In the latest session, Immuneering Corp (NASDAQ: IMRX) closed at $1.91 down -8.81% from its previous closing price of $2.10. On the day, 856336 shares were traded. IMRX stock price reached its highest trading level at $2.0800 during the session, while it also had its lowest trading level at $1.8900.
Ratios:
For a deeper understanding of Immuneering Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.35 and its Current Ratio is at 11.35. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 15, 2024, Reiterated its Buy rating but revised its target price to $15 from $20 previously.
Jefferies Downgraded its Buy to Hold on March 15, 2024, whereas the target price for the stock was revised from $16 to $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 01 ’24 when Cormorant Asset Management, LP sold 400,000 shares for $2.90 per share. The transaction valued at 1,160,181 led to the insider holds 2,895,273 shares of the business.
Feinberg Peter bought 25,000 shares of IMRX for $63,713 on Mar 22 ’24. The Director now owns 111,766 shares after completing the transaction at $2.55 per share. On Mar 22 ’24, another insider, Brakewood Harold Eugene, who serves as the Chief Business Officer of the company, bought 3,900 shares for $2.57 each. As a result, the insider paid 10,015 and bolstered with 3,900 shares of the company.
Stock Price History:
Over the past 52 weeks, IMRX has reached a high of $14.29, while it has fallen to a 52-week low of $1.90.
Shares Statistics:
A total of 29.27M shares are outstanding, with a floating share count of 20.63M. Insiders hold about 29.56% of the company’s shares, while institutions hold 46.76% stake in the company.
Earnings Estimates
There are ImmunityBio, Inc. different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $16.33, with high estimates of $5.54 and low estimates of $1.31.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Communication Services.
